Novartis India [NOVARTIND] vs Sun Pharmaceutical [SUNPHARMA] Detailed Stock Comparison

Novartis India Ltd.

BSE
Loading...

Sun Pharmaceutical Industries Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Novartis India Ltd. wins in 10 metrics, Sun Pharmaceutical Industries Ltd. wins in 10 metrics, with 0 ties. Both stocks appear equally matched on key metrics.

View Metrics Details

Vital Metrics Comparison

Metric Novartis India Ltd. Sun Pharmaceutical Industries Ltd. Better
P/E Ratio (TTM) 25.00 36.73 Novartis India Ltd.
Price-to-Book Ratio 3.14 5.15 Novartis India Ltd.
Debt-to-Equity Ratio 0.52 6.68 Novartis India Ltd.
PEG Ratio -1.18 3.59 Sun Pharmaceutical Industries Ltd.
EV/EBITDA 20.21 23.61 Novartis India Ltd.
Profit Margin (TTM) 27.97% 19.21% Novartis India Ltd.
Operating Margin (TTM) 25.47% 26.17% Sun Pharmaceutical Industries Ltd.
EBITDA Margin (TTM) 25.47% 26.17% Sun Pharmaceutical Industries Ltd.
Return on Equity 12.85% 15.08% Sun Pharmaceutical Industries Ltd.
Return on Assets (TTM) 10.65% 11.87% Sun Pharmaceutical Industries Ltd.
Free Cash Flow (TTM) $745.70M $119.44B Sun Pharmaceutical Industries Ltd.
Dividend Yield 2.44% 0.97% Novartis India Ltd.
1-Year Return 49.33% 7.25% Novartis India Ltd.
Price-to-Sales Ratio (TTM) 7.00 7.05 Novartis India Ltd.
Enterprise Value $18.37B $3,783.37B Sun Pharmaceutical Industries Ltd.
EV/Revenue Ratio 5.29 6.66 Novartis India Ltd.
Gross Profit Margin (TTM) 43.07% 80.96% Sun Pharmaceutical Industries Ltd.
Revenue per Share (TTM) $141 $237 Sun Pharmaceutical Industries Ltd.
Earnings per Share (Diluted) $39.42 $45.46 Sun Pharmaceutical Industries Ltd.
Beta (Stock Volatility) -0.05 0.11 Novartis India Ltd.

Novartis India Ltd. vs Sun Pharmaceutical Industries Ltd. Stock Performance Analysis

Loading Price Chart...

NOVARTIND
SUNPHARMA

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Novartis India Ltd.-9.47%-10.87%29.78%44.07%63.91%70.30%
Sun Pharmaceutical Industries Ltd.-0.08%-3.03%-1.92%2.17%-1.01%3.92%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Novartis India Ltd.49.33%115.71%137.09%117.42%110.10%222.44%
Sun Pharmaceutical Industries Ltd.7.25%79.99%166.96%144.01%669.48%2,278.32%

Performance & Financial Health Analysis: Novartis India Ltd. vs Sun Pharmaceutical Industries Ltd.

MetricNOVARTINDSUNPHARMA
Market Information
Market Cap i₹23.65B₹3.88T
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i10,6933,903,142
90 Day Avg. Volume i14,0373,253,866
Last Close₹1,326.20₹1,788.50
52 Week Range₹750.00 - ₹1,588.40₹1,548.00 - ₹1,916.60
% from 52W High-16.51%-6.68%
All-Time High₹1,588.40 (Jun 01, 2026)₹1,960.35 (Sep 30, 2024)
% from All-Time High-16.51%-8.77%
Growth Metrics
Quarterly Revenue Growth-0.08%0.14%
Quarterly Earnings Growth-0.37%0.16%
Financial Health
Profit Margin (TTM) i0.28%0.19%
Operating Margin (TTM) i0.25%0.26%
Return on Equity (TTM) i0.13%0.15%
Debt to Equity (MRQ) i0.526.68
Cash & Liquidity
Book Value per Share (MRQ)₹313.93₹324.46
Cash per Share (MRQ)₹250.14₹115.87
Operating Cash Flow (TTM) i₹997.00M₹110.84B
Levered Free Cash Flow (TTM) i₹1.01B₹109.29B
Dividends
Last 12-Month Dividend Yield i2.44%0.97%
Last 12-Month Dividend i₹25.00₹16.50

Valuation & Enterprise Metrics Analysis: Novartis India Ltd. vs Sun Pharmaceutical Industries Ltd.

MetricNOVARTIND (Apr 24, 2026)SUNPHARMA (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i25.0036.73
Forward P/E iN/A29.48
PEG Ratio i-1.183.59
Price to Sales (TTM) i7.007.05
Price to Book (MRQ) i3.145.15
Market Capitalization
Market Capitalization i₹23.65B₹3.88T
Enterprise Value i₹18.37B₹3.78T
Enterprise Value Metrics
Enterprise to Revenue i5.296.66
Enterprise to EBITDA i20.2123.61
Risk & Other Metrics
Beta i-0.050.11
Book Value per Share (MRQ) i₹313.93₹324.46

Financial Statements Comparison: Novartis India Ltd. vs Sun Pharmaceutical Industries Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricNOVARTIND (2025)SUNPHARMA (2025)
Revenue/Sales i3.56B520.41B
Cost of Goods Sold i2.06B121.98B
COGS % of Revenue i57.7%23.4%
Gross Profit i1.51B398.44B
Gross Margin i42.3%76.6%
Research & Development iN/AN/A
Operating Income (EBIT) i941.70M125.81B
Operating Margin i26.4%24.2%
EBITDA i1.38B167.25B
EBITDA Margin i38.7%32.1%
Pre-Tax Income i1.30B137.52B
Pre-Tax Income % of Revenue i36.6%26.4%
Income Tax i295.20M27.72B
Income Tax % of Revenue i8.3%5.3%
Net Income (Profit) i1.01B109.65B
Profit Margin i28.3%21.1%

Balance Sheet & Liquidity Metrics

MetricNOVARTIND (2025)SUNPHARMA (2025)
Cash & Equivalents i520.70M102.69B
Total Current Assets i7.46B526.24B
Total Current Assets % of Revenue i209.3%101.1%
Total Current Liabilities i1.42B181.94B
Total Current Liabilities % of Revenue i39.9%35.0%
Long-Term Debt i32.10M3.58B
Long-Term Debt % of Revenue i0.9%0.7%
Total Shareholders Equity i7.85B724.86B
Retained Earnings i7.69B578.62B
Retained Earnings % of Revenue i215.8%111.2%
Property, Plant & Equipment i35.70M100.36B

Cash Flow Statement Comparison

MetricNOVARTIND (2025)SUNPHARMA (2025)
Operating Cash Flow i997.00M110.84B
Operating Cash Flow % of Revenue i28.0%21.3%
Capital Expenditures i3.20M-20.68B
Free Cash Flow i745.70M119.44B
FCF Margin i20.9%23.0%
Debt Repayment iN/A-43.44B
Common Stock Repurchase iN/A-29.00B

Short Interest & Institutional Ownership Analysis

MetricNOVARTINDSUNPHARMA
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i24.69M2.40B
Float Shares i6.69M1.07B
% Held by Insiders i72.92%55.62%
% Held by Institutions i0.16%28.69%
% Held by Public i26.92%15.69%

Dividend Analysis & Yield Comparison: Novartis India Ltd. vs Sun Pharmaceutical Industries Ltd.

MetricNOVARTINDSUNPHARMA
Last 12-Month Dividend i₹25.00₹16.50
Last 12-Month Dividend Yield i2.44%0.97%
3-Year Avg Annual Dividend i₹32.50₹17.33
3-Year Avg Dividend Yield i3.57%0.51%
3-Year Total Dividends i₹97.50₹52.00
Ex-Dividend DateJul 23, 2025Feb 05, 2026